About FLC
- Free Light Chains are immunoglobulin light chains that are circulating in serum in a free state (unbound). Kappa (κ) and Lambda (λ) are the two types of immunoglobulin light chains produced in humans.
- The quantification of serum FLC is used as an aid in the diagnosis and monitoring of patients with Multiple Myeloma and AL Amyloidosis.
- A patient’s FLC ratio (kappa FLC/lambda FLC), when compared to a diagnostic reference range, may indicate the presence of certain plasma cell disorders such as Multiple Myeloma and AL Amyloidosis.
Key benefits
Superior Clinical Results
17% higher specificity compared to immunoassay, while reducing the impacts of antigen excess and polymerization
Decreased Repeat Rate
Up to 4x fewer repeats compared to immunoassay, saves valuable laboratory resources and lowering the cost of the analysis.
Clinical Performance
Equivalent clinical cut-off criteria (rFLC >100 can be used for diagnosis of MM and rFLC >20 as SMM progression criterion).
Main characteristics
Quantification of Kappa or Lambda Free Light Chains is performed with an Enzyme-Linked Immunosorbent Assay (ELISA) procedure utilizing specific antibodies anti-Kappa or anti-Lambda free light chains.
Serum sample
96 well microplate in strip format.
- FLC Kappa – P/N: 5102
- FLC Lambda – P/N: 5103
- FLC Control Level 1 – P/N: 5112
- FLC Control Level 2 – P/N: 5113
Related resources
See all resourcesAL Amyloidosis: Role of clinical lab in diagnosis and management
Educational Webinar with Prof. Giovanni PALLADINI, PhD
Current Status of Detecting Monoclonal Antibodies and Free Light Chains in Serum
Educational Webinar with Dr. Matthias Orth from University of Heidelberg at University Hospital Mannheim.
Complete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Scientific publications
See all publicationsMultiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.